Overview

Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
0
Participant gender:
All
Summary
To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Affiliated Hospital of Nanchang University
Treatments:
Cyclosporine
Cyclosporins
Loteprednol Etabonate
Ophthalmic Solutions
Tobramycin
Criteria
Inclusion criteria

- patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning,
stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;

- Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal
hypertrophy, Horner-Trantas dots, Keratitis in some patients;

- No other medication history in recent 2 weeks;

- Patients have high compliance and are willing to take drugs on time and return to the
clinic in time

Exclusion criteria:

- with other related immune diseases or other drug use history in recent 2 weeks;

- Patients with evident and severe organic diseases or mental diseases;

- Low compliance, unable to take drugs on time or fail to return to the clinic on time.